AZ LICENSES ZURAMPIC TO GRÜNENTHAL GMBH
02 juin 2016 02h00 HE
|
AstraZeneca PLC
ASTRAZENECA LICENSES ZURAMPIC TO
GRÜNENTHAL GMBH IN EUROPE AND LATIN AMERICA
Agreement includes rights to the fixed-dose combination of lesinurad and
allopurinol in gout
AstraZeneca today...
POSITIVE CHMP OPINION IN EU FOR SAXA/DAPA
27 mai 2016 07h53 HE
|
AstraZeneca PLC
POSITIVE CHMP OPINION IN EU FOR SAXA/DAPA (SAXAGLIPTIN AND DAPAGLIFLOZIN) FOR
ADULTS WITH TYPE-2 DIABETES
AstraZeneca today announced that the Committee for Medicinal Products for Human
Use (CHMP) of...
ASTRAZENECA'S FASLODEX MET PRIMARY ENDPOINT IN FIRST-LINE TREATMENT OF ADVANCED BREAST CANCER
27 mai 2016 02h03 HE
|
AstraZeneca PLC
AstraZeneca today announced positive results from the Phase III FALCON trial
comparing Faslodex 500mg (fulvestrant) to Arimidex 1mg (anastrozole) for the
treatment of locally-advanced or metastatic...
ASTRAZENECA RECEIVES COMPLETE RESPONSE LETTER FROM US FDA FOR SODIUM ZIRCONIUM CYCLOSILICATE (ZS-9) FOR ORAL SUSPENSION FOR TREATMENT OF HYPERKALAEMIA
27 mai 2016 02h00 HE
|
AstraZeneca PLC
27 May 2016
AstraZeneca today announced that the US Food and Drug Administration (FDA) has
issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA)
for sodium zirconium...
Director/PDMR Shareholding
23 mai 2016 11h00 HE
|
AstraZeneca PLC
Transaction by Person Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4
On 23 May 2016, the interest of Luke Miels, a person discharging managerial
responsibilities, in AstraZeneca...
TOP-LINE RESULTS FROM LYNPARZA GOLD TRIAL
18 mai 2016 02h00 HE
|
AstraZeneca PLC
ASTRAZENECA PROVIDES TOP-LINE RESULTS FROM LYNPARZA GOLD TRIAL IN ADVANCED
GASTRIC CANCER
18 May 2016
AstraZeneca today announced that Lynparza (olaparib) in combination with
paclitaxel...
POSITIVE BENRALIZUMAB RESULTS IN SEVERE ASTHMA
17 mai 2016 02h00 HE
|
AstraZeneca PLC
ASTRAZENECA ANNOUNCES POSITIVE RESULTS FROM BENRALIZUMAB
PHASE III PROGRAMME IN SEVERE ASTHMA
Benralizumab first AstraZeneca respiratory biologic to complete Phase III
17 May 2016
AstraZeneca today...
SELUMETINIB GRANTED ORPHAN DRUG DESIGNATION IN US
12 mai 2016 02h00 HE
|
AstraZeneca PLC
SELUMETINIB granted Orphan Drug Designation in the US for ADJUVANT treatment of
Differentiated thyroid cancer
AstraZeneca today announced that the US Food and Drug Administration (FDA) has
granted...
Publication of Final Terms
11 mai 2016 10h30 HE
|
AstraZeneca PLC
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION WHERE TO DO SO
WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
Publication of Final Terms in relation to the...
Launch and pricing of EUR2.2bn bond issues
09 mai 2016 12h52 HE
|
AstraZeneca PLC
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION WHERE TO DO SO
WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
AstraZeneca launches and prices bond issues of...